-

01:15:12 AM

AEMD Stock News

AEMD - Aethlon Medical Inc

05/24/22 4:21 PM

Nasdaq : AEMD

low float

/C O R R E C T I O N -- Aethlon Medical, Inc./

In the news release, Aethlon Medical to Present at the H.C. Wainwright Global Investment Conference, issued 17-May-2022 by Aethlon Medical, Inc. over PR Newswire, we are advised by the company that in the "Company Webcasting Link" section, the link should only be directing to

RHEA-AI

neutral

05/17/22 8:01 AM

Nasdaq : AEMD

conferenceslow float

Aethlon Medical to Present at the H.C. Wainwright Global Investment Conference

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced that it will be presenting at the H.C. Wainwright Global Investment Conference. The

RHEA-AI

neutral

05/02/22 8:01 AM

Nasdaq : AEMD

covid-19low float

Aethlon Medical Publishes In Vitro Studies Demonstrating Hemopurifier Resin Binding of Seven Clinically Relevant COVID-19 Variants

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced

RHEA-AI

neutral

03/28/22 8:01 AM

Nasdaq : AEMD

managementlow float

Aethlon Medical, Inc. Appoints Angela Rossetti to Board of Directors

Aethlon Medical, Inc. ("Aethlon") (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced the appointment of Angela Rossetti to the Aethlon Board of Directors,

RHEA-AI

very positive

02/14/22 4:15 PM

Nasdaq : AEMD

earningslow float

Aethlon Medical Announces Third Quarter Financial Results and Provides Corporate Update

Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious diseases, today reported financial results for its third quarter ended December 31, 2021 and provided an update on recent

RHEA-AI

neutral

01/31/22 8:01 AM

Nasdaq : AEMD

earningslow float

Aethlon Medical to Release Third Quarter Financial Results and Host Conference Call on February 14, 2022

Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its third quarter fiscal year 2022, ended December 31, 2021, at

RHEA-AI

neutral

11/09/21 4:15 PM

Nasdaq : AEMD

earningslow float

Aethlon Medical Announces Second Quarter Financial Results and Provides Corporate Update

Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious diseases, today reported financial results for its second quarter ended September 30, 2021 and provided an update on recent

RHEA-AI

neutral

11/02/21 8:02 AM

Nasdaq : AEMD

earningslow float

Aethlon Medical to Release Second Quarter Financial Results and Host Conference Call on November 9, 2021

Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its second quarter fiscal year 2022, ended September 30, 2021, at

RHEA-AI

neutral

10/12/21 8:01 AM

Nasdaq : AEMD

covid-19low float

Aethlon Medical Announces Peer-Reviewed Publication of Two Case Studies of Critically Ill COVID-19 Patients Treated with the Hemopurifier®

Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced the publication of a manuscript in the peer-reviewed journal Frontiers in Medicine describing two cases of

RHEA-AI

neutral

09/30/21 8:02 AM

Nasdaq : AEMD, PPD

low float

Aethlon Medical Announces Contracting with PPD to Advance Hemopurifier Clinical Programs

Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it has entered into an agreement with PPD, Inc. (Nasdaq: PPD), a leading global contract research

RHEA-AI

neutral